As a result of a transaction announced last week.
By Goldman Sachs.
The rating is 'Buy'.
New details published about Mol vs. Croatia case.
Bank of America Merrill Lynch says you should buy Mol.
The best solutions would be a new strategic partner.
Good news, as transparency grows.
On over 12,000 shares.
Plotinus had enough of the burdens of being listed.
In female healthcare product acquistions.
The costs of the lawsuit have already been high.
By Deutsche Bank.
With UniCredit.
No share movement, only financial settlement.